BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 83.2%

Neg 0% Neu 0% Pos 83.2%

BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $53 to $65.